Acta Med. 2010, 53: 85-91

A Comparison of the Potency of Newly Developed Oximes (K347, K628) and Currently Available Oximes (Obidoxime, HI-6) to Counteract Acute Neurotoxic Effects of Tabun in Rats

Jiří Kassaa, Jana Žďárová Karasováa, Sandra Tesařováb, Kamil Musíleka, Kamil Kučac

aUniversity of Defence, Faculty of Military Health Sciences, Department of Toxicology, Hradec Králové, Czech Republic
bThe 7th Field Hospital of the Czech Army, Hradec Králové, Czech Republic
cUniversity of Defence, Faculty of Military Health Sciences, Center of Advanced Studies, Hradec Králové, Czech Republic

Received February 26, 2010
Accepted May 10, 2010


1. Cabal J, Bajgar J. Tabun – reappearance 50 years later (in Czech). Chem Listy 1999; 93:27–31.
2. Cabal J, Kuca K, Kassa J. Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase. Bas Clin Pharmacol Toxicol 2004; 95:81–6. <>
3. Cassel G, Karlsson L, Waara L, Wee Ang K, Goransson-Nyberg A. Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur J Pharmacol 1997; 332:43–52. <>
4. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994; 14:317–31. <>
5. Dohnal V, Kuca K, Jun D. Prediction of a new broad-spectrum reactivator capable of reactivating acetylcholinesterase inhibited by nerve agents. J Appl Toxicol 2005; 3:139–45.
6. Ekström F, Akfur C, Tunemalm AK, Lundberg S. Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry 2006; 45:74–81. <>
7. Frantik E, Hornychova M. Clustering of neurobehavioral measures of toxicity. Homeostasis 1995; 36:19–25.
8. Hornychova M, Frantik E, Kubat J, Formanek J. Neurotoxicity profile of supermethrin, a new pyrethroid insecticide. Cent Eur J Pub Health 1995; 3:210–8.
9. Jokanovic M. Anticholinesterase activity and delayed neurotoxic effects of tabun in hens. Voj Preg 1993; 50:451–6.
10. Jokanovic M, Maksimovic M, Kilibarda V, Jovanovic D, Savic D. Oxime-induced reactivation of acetycholinesterase inhibited by phosphoramidates. Toxicol Lett 1996; 85:35–9. <>
11. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002; 40:803–16. <>
12. Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with currently available oximes and H oximes against soman by in vitro and in vivo methods. Toxicology 1999; 132:111–8. <>
13. Kassa J, Cabal J, Kuca K. A comparison of the efficacy of currently available oximes against tabun in rats. Biologia 60/Suppl. 2005; 17:77–9.
14. Kassa J, Karasova J. The evaluation of the neuroprotective effects of bispyridinium oximes in tabun-poisoned rats. J Toxicol Environ Health, Part A 2007; 70: 1556–67. <>
15. Kassa J, Krejcova G: Neuroprotective effects of currently used antidotes in tabunpoisoned rats. Pharmacol. Toxicol. 92: 258–264, 2003. <>
16. Kassa J, Kuca K, Bartosova L, Kunesova G. The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem 2007; 11:267–83. <>
17. Kassa J, Kunesova G. Comparison of the neuroprotective effects of the newly developed oximes (K027, K048) with trimedoxime in tabun-poisoned rats. J Appl Biomed 2006; 4:123–34.
18. Koplovitz I, Stewart JR. A comparison of the efficacy of HI-6 and 2-PAM against soman, tabun, sarin and VX in the rabbit. Toxicol Lett 1994; 70:169–79. <>
19. Kuca K, Jun D, Musilek K. Structural requirements of acetylcholinesterase reactivators. Mini-Rev Med Chem 2006; 6:109–20. <>
20. Kuca K, Musilek K, Jun D, Pohanka M, Zdarova Karasova J, Novotny L, Musilova L. Could oxime HI-6 really be considered as „broad-spectrum“ antidote? J Appl Biomed 2009; 7:143–9.
21. Lotti M. Organophosphorus compounds. In: Spencer PS, Schaumburg HH (eds). Experimental and Clinical Neurotoxicology. New York: Oxford University Press 2000:898–925.
22. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58:51–66. <>
23. Moser VC, Tilson H, McPhail RC, Becking GC, Cuomo V, Frantik E, Kulig BM, Winneke, G. The IPCS collaborative study on neurobehavioral screening methods: II. Protocol design and testing procedures. Neurotoxicology 1997; 18: 929–38.
24. Musilek K, Kuca K, Jun D, Dolezal M. In vitro reactivation potency of bispyridinium (E)-but-ene linked acetylcholinesterase reactivators against tabun-inhibited acetylcholinesterase. J Appl Biomed 2007; 5:25–30.
25. Musilek K, Kucera J, Jun D, Dohnal V, Opletalova V, Kuca K. Monoquaternary pyridinium salts with modified side chain – synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorg Med Chem 2008; 16: 8218–23. <>
26. Puu G, Artursson E, Bucht G. Reactivation of nerve agent inhibited acetylcholinesterase by HI-6 and obidoxime. Biochem Pharmacol 1986; 35:1505–10. <>
27. Roth Z, Josifko M, Maly V, Trcka V. Statistical Methods in Experimental Medicine (in Czech), SZN Prague, 1962.
28. Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K, Toshibo M, Sakai I, Mukoyama H, Takatori T. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 2003; 28:1401–7. <>
29. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE (eds). The Pharmacological Basis of Therapeutics. New York: McGraw Hill 1996:161–76.
30. Worek F, Widmann R, Knopff O, Szinicz L. Reactivating potency of obidoxime, pralidoxime, HI-6 and HLö-7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 1998; 72: 237–43. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal